IDO2 and neoplasm: However, we observed that the inhibitory tumor microenvironment ultimately hampers clinical efficacy: following CAR T cell administration, several immunosuppressive factors were upregulated in the tumor environment including programmed death-ligand 1 (PD-L1), tryptophan 2,3-dioxygenase, indoleamine 2,3-dioxygenase, and IL-10.